Aclaris Therapeutics, Inc. (ACRS) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
37/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinACRS / S&P 41.07% / 15.20% |
LoseACRS / S&P -51.05% / 15.00% |
LoseACRS / S&P -63.06% / 50.40% |
| 2026-Q11/3 |
WinACRS / S&P 24.58% / -4.33% |
LoseACRS / S&P -52.94% / 11.30% |
LoseACRS / S&P -64.78% / 27.70% |
| 2025-Q41/3 |
WinACRS / S&P 58.42% / 2.65% |
LoseACRS / S&P -58.20% / 9.00% |
LoseACRS / S&P -69.01% / 13.40% |
| 2025-Q32/3 |
WinACRS / S&P 33.80% / 8.12% |
LoseACRS / S&P -41.87% / 4.61% |
WinACRS / S&P 203.85% / 13.45% |
| 2025-Q21/3 |
LoseACRS / S&P -7.19% / 10.94% |
LoseACRS / S&P -47.56% / 4.83% |
WinACRS / S&P 91.46% / 10.63% |
| 2025-Q11/3 |
LoseACRS / S&P -38.31% / -4.27% |
LoseACRS / S&P -42.87% / 4.98% |
WinACRS / S&P 45.87% / 10.57% |
| 2024-Q42/3 |
WinACRS / S&P 115.65% / 2.41% |
LoseACRS / S&P -40.09% / 5.25% |
WinACRS / S&P 34.65% / 6.15% |
| 2024-Q31/3 |
LoseACRS / S&P 4.55% / 5.89% |
WinACRS / S&P 26.35% / 5.89% |
LoseACRS / S&P -68.67% / 6.11% |
| 2024-Q20/3 |
LoseACRS / S&P -11.29% / 4.28% |
LoseACRS / S&P 2.72% / 5.38% |
LoseACRS / S&P -47.10% / 5.12% |
| 2024-Q11/3 |
WinACRS / S&P 18.10% / 10.56% |
LoseACRS / S&P 0.95% / 5.71% |
LoseACRS / S&P -24.31% / 5.59% |
| 2023-Q40/3 |
LoseACRS / S&P -84.67% / 11.69% |
LoseACRS / S&P 5.03% / 6.81% |
LoseACRS / S&P -4.51% / 7.78% |
| 2023-Q31/3 |
LoseACRS / S&P -33.94% / -3.27% |
LoseACRS / S&P -8.80% / 7.52% |
WinACRS / S&P 28.68% / -5.03% |
| 2023-Q23/3 |
WinACRS / S&P 28.18% / 8.74% |
WinACRS / S&P 407.54% / 9.50% |
WinACRS / S&P 15.67% / -8.57% |
| 2023-Q12/3 |
LoseACRS / S&P -48.63% / 7.50% |
WinACRS / S&P 378.90% / 10.77% |
WinACRS / S&P 5.11% / -15.69% |
| 2022-Q41/3 |
LoseACRS / S&P 0.06% / 7.56% |
WinACRS / S&P 340.05% / 11.88% |
LoseACRS / S&P -18.40% / -17.99% |
| 2022-Q32/3 |
WinACRS / S&P 12.75% / -4.88% |
WinACRS / S&P 243.57% / 13.47% |
LoseACRS / S&P ACRS unavailable / -1.41% |
| 2022-Q20/3 |
LoseACRS / S&P -19.03% / -16.10% |
LoseACRS / S&P -7.38% / 13.71% |
LoseACRS / S&P ACRS unavailable / 11.04% |
| 2022-Q11/3 |
WinACRS / S&P 18.57% / -4.60% |
LoseACRS / S&P -6.06% / 15.97% |
LoseACRS / S&P ACRS unavailable / 42.23% |
| 2021-Q40/3 |
LoseACRS / S&P -19.22% / 11.03% |
LoseACRS / S&P 4.30% / 15.00% |
LoseACRS / S&P ACRS unavailable / 96.40% |
| 2021-Q32/3 |
WinACRS / S&P 2.51% / 0.58% |
WinACRS / S&P 14.06% / 10.77% |
LoseACRS / S&P ACRS unavailable / 69.42% |
| 2021-Q21/3 |
LoseACRS / S&P -30.32% / 8.55% |
WinACRS / S&P 19.87% / 6.58% |
LoseACRS / S&P ACRS unavailable / 51.81% |
| 2021-Q12/3 |
WinACRS / S&P 289.49% / 6.17% |
WinACRS / S&P 56.76% / -1.06% |
LoseACRS / S&P ACRS unavailable / 7.39% |
| 2020-Q42/3 |
WinACRS / S&P 151.75% / 12.15% |
WinACRS / S&P 53.35% / -3.72% |
LoseACRS / S&P ACRS unavailable / -33.42% |
| 2020-Q32/3 |
WinACRS / S&P 58.64% / 8.93% |
WinACRS / S&P 22.29% / -2.04% |
LoseACRS / S&P ACRS unavailable / -27.10% |
| 2020-Q22/3 |
WinACRS / S&P 55.77% / 20.54% |
WinACRS / S&P 9.76% / -0.46% |
LoseACRS / S&P ACRS unavailable / -27.11% |
| 2020-Q10/3 |
LoseACRS / S&P -44.97% / -19.60% |
LoseACRS / S&P -44.17% / 3.47% |
LoseACRS / S&P ACRS unavailable / -14.75% |
| 2019-Q41/3 |
WinACRS / S&P 75.00% / 9.07% |
LoseACRS / S&P -44.99% / 5.36% |
LoseACRS / S&P ACRS unavailable / 2.99% |
| 2019-Q30/3 |
LoseACRS / S&P -50.68% / 1.70% |
LoseACRS / S&P -29.04% / 5.02% |
LoseACRS / S&P ACRS unavailable / 0.21% |
| 2019-Q20/3 |
LoseACRS / S&P -63.44% / 4.30% |
LoseACRS / S&P -22.20% / 6.64% |
LoseACRS / S&P ACRS unavailable / 8.65% |
| 2019-Q10/3 |
LoseACRS / S&P -18.94% / 13.65% |
LoseACRS / S&P ACRS unavailable / 8.12% |
LoseACRS / S&P ACRS unavailable / 14.29% |
| 2018-Q40/3 |
LoseACRS / S&P -49.10% / -13.52% |
LoseACRS / S&P ACRS unavailable / 9.05% |
LoseACRS / S&P ACRS unavailable / 18.23% |
| 2018-Q30/3 |
LoseACRS / S&P -27.29% / 7.71% |
LoseACRS / S&P ACRS unavailable / 10.21% |
LoseACRS / S&P ACRS unavailable / 19.06% |
| 2018-Q21/3 |
WinACRS / S&P 13.98% / 3.43% |
LoseACRS / S&P ACRS unavailable / 9.03% |
LoseACRS / S&P ACRS unavailable / 14.46% |
| 2018-Q10/3 |
LoseACRS / S&P -28.95% / -0.76% |
LoseACRS / S&P ACRS unavailable / 7.68% |
LoseACRS / S&P ACRS unavailable / 12.46% |
| 2017-Q40/3 |
LoseACRS / S&P -4.46% / 6.64% |
LoseACRS / S&P ACRS unavailable / 7.03% |
LoseACRS / S&P ACRS unavailable / 13.82% |
| 2017-Q30/3 |
LoseACRS / S&P -4.83% / 4.48% |
LoseACRS / S&P ACRS unavailable / 5.68% |
LoseACRS / S&P ACRS unavailable / 17.57% |
| 2017-Q20/3 |
LoseACRS / S&P -9.05% / 3.09% |
LoseACRS / S&P ACRS unavailable / 4.83% |
LoseACRS / S&P ACRS unavailable / 17.74% |
| 2017-Q11/3 |
WinACRS / S&P 9.87% / 6.07% |
LoseACRS / S&P ACRS unavailable / 3.67% |
LoseACRS / S&P ACRS unavailable / 13.32% |
| 2016-Q41/3 |
WinACRS / S&P 5.97% / 3.82% |
LoseACRS / S&P ACRS unavailable / 2.09% |
LoseACRS / S&P ACRS unavailable / 7.05% |
| 2016-Q31/3 |
WinACRS / S&P 38.66% / 3.85% |
LoseACRS / S&P ACRS unavailable / 0.20% |
LoseACRS / S&P ACRS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ACRS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 219.17% | 20.78% |
| Annualized return | 219.17% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ACRS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -64.23% | 83.14% |
| Annualized return | -18.58% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | ACRS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -70.21% | 319.30% |
| Annualized return | -11.41% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |